• Something wrong with this record ?

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

SZ. Usmani, T. Facon, V. Hungria, NJ. Bahlis, CP. Venner, M. Braunstein, L. Pour, JM. Martí, S. Basu, YC. Cohen, M. Matsumoto, K. Suzuki, C. Hulin, S. Grosicki, W. Legiec, M. Beksac, A. Maiolino, H. Takamatsu, A. Perrot, M. Turgut, T. Ahmadi, W....

. 2025 ; 31 (4) : 1195-1202. [pub] 20250205

Language English

Document type Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25016281

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10-5 by next-generation sequencing. Major secondary endpoints included complete response (CR) or better (≥CR) rate, progression-free survival and sustained MRD-negativity rate at 10-5. At a median follow-up of 58.7 months, the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58-3.55; P < 0.0001). Rates of ≥CR (81.2% versus 61.6%; P < 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001) were significantly higher with D-VRd versus VRd. Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41-0.79; P = 0.0005). Adverse events were consistent with the known safety profiles for daratumumab and VRd. Combining daratumumab with VRd produced deeper and more durable MRD responses versus VRd alone. The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM. ClinicalTrials.gov registration: NCT03652064 .

Arnie Charbonneau Cancer Research Institute University of Calgary Calgary Alberta Canada

BC Cancer Vancouver Centre University of British Columbia Vancouver British Columbia Canada

CHU de Toulouse IUCT O Université de Toulouse UPS Service d'Hématologie Toulouse France

Clínica Médica São Germano São Paulo Brazil

Department of Hematology Amsterdam UMC Vrije Universiteit Amsterdam Cancer Center Amsterdam Amsterdam The Netherlands

Department of Hematology and Bone Marrow Transplantation St John of Dukla Oncology Center of Lublin Land Lublin Poland

Department of Hematology and Cancer Prevention School of Public Health Medical University of Silesia Katowice Poland

Department of Hematology Hôpital Haut Lévêque University Hospital Pessac France

Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

Department of Hematology Kanazawa University Hospital Kanazawa University Kanazawa Japan

Department of Hematology National Hospital Organization Shibukawa Medical Center Gunma Japan

Department of Hematology Ondokuz Mayıs University Faculty of Medicine Samsun Turkey

Department of Hematology Tel Aviv Sourasky Medical Center Tel Aviv Israel

Department of Medical Oncology Cross Cancer Institute University of Alberta Edmonton Alberta Canada

Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel

Genmab US Inc Plainsboro NJ USA

Hospital Universitario Mútua de Terrassa Terrassa Spain

Instituto Americas de Ensino Pesquisa e Inovação Rio de Janeiro Brazil

Istinye University Ankara Liv Hospital Ankara Turkey

Johnson and Johnson High Wycombe UK

Johnson and Johnson Leiden The Netherlands

Johnson and Johnson Raritan NJ USA

Johnson and Johnson Shanghai China

Johnson and Johnson Spring House PA USA

Memorial Sloan Kettering Cancer Center New York NY USA

Perlmutter Cancer Center NYU Langone Health New York NY USA

Royal Wolverhampton NHS Trust and University of Wolverhampton CRN West Midlands National Institute for Health and Care Research Wolverhampton UK

Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil

University Hospital Brno Brno Czech Republic

University of Lille CHU de Lille Service des Maladies du Sang Lille France

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016281
003      
CZ-PrNML
005      
20250731092800.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41591-024-03485-7 $2 doi
035    __
$a (PubMed)39910273
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Usmani, Saad Z $u Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org $1 https://orcid.org/0000000254848731
245    10
$a Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial / $c SZ. Usmani, T. Facon, V. Hungria, NJ. Bahlis, CP. Venner, M. Braunstein, L. Pour, JM. Martí, S. Basu, YC. Cohen, M. Matsumoto, K. Suzuki, C. Hulin, S. Grosicki, W. Legiec, M. Beksac, A. Maiolino, H. Takamatsu, A. Perrot, M. Turgut, T. Ahmadi, W. Liu, J. Wang, K. Chastain, J. Vermeulen, M. Krevvata, L. Lopez-Masi, J. Carey, M. Rowe, R. Carson, S. Zweegman
520    9_
$a Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10-5 by next-generation sequencing. Major secondary endpoints included complete response (CR) or better (≥CR) rate, progression-free survival and sustained MRD-negativity rate at 10-5. At a median follow-up of 58.7 months, the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58-3.55; P < 0.0001). Rates of ≥CR (81.2% versus 61.6%; P < 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001) were significantly higher with D-VRd versus VRd. Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41-0.79; P = 0.0005). Adverse events were consistent with the known safety profiles for daratumumab and VRd. Combining daratumumab with VRd produced deeper and more durable MRD responses versus VRd alone. The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM. ClinicalTrials.gov registration: NCT03652064 .
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x diagnóza $x mortalita $x patologie $7 D009101
650    12
$a lenalidomid $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000077269
650    12
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003907
650    12
$a bortezomib $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000069286
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D000971
650    _2
$a lidé středního věku $7 D008875
650    12
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000911
650    _2
$a reziduální nádor $7 D018365
650    _2
$a dospělí $7 D000328
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Facon, Thierry $u University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France
700    1_
$a Hungria, Vania $u Clínica Médica São Germano, São Paulo, Brazil
700    1_
$a Bahlis, Nizar J $u Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada $1 https://orcid.org/0000000173537034
700    1_
$a Venner, Christopher P $u Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada $u BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Braunstein, Marc $u Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
700    1_
$a Pour, Ludek $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Martí, Josep M $u Hospital Universitario Mútua de Terrassa, Terrassa, Spain
700    1_
$a Basu, Supratik $u Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK $1 https://orcid.org/0000000322064796
700    1_
$a Cohen, Yael C $u Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel $u Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000290617287
700    1_
$a Matsumoto, Morio $u Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan
700    1_
$a Suzuki, Kenshi $u Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
700    1_
$a Hulin, Cyrille $u Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
700    1_
$a Grosicki, Sebastian $u Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland
700    1_
$a Legiec, Wojciech $u Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland
700    1_
$a Beksac, Meral $u Istinye University, Ankara Liv Hospital, Ankara, Turkey
700    1_
$a Maiolino, Angelo $u Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil $u Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil $1 https://orcid.org/0000000301409548
700    1_
$a Takamatsu, Hiroyuki $u Department of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan
700    1_
$a Perrot, Aurore $u CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France $1 https://orcid.org/0000000301318689
700    1_
$a Turgut, Mehmet $u Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey
700    1_
$a Ahmadi, Tahamtan $u Genmab US, Inc., Plainsboro, NJ, USA
700    1_
$a Liu, Weiping $u Johnson & Johnson, Shanghai, China
700    1_
$a Wang, Jianping $u Johnson & Johnson, Spring House, PA, USA
700    1_
$a Chastain, Katherine $u Johnson & Johnson, Raritan, NJ, USA
700    1_
$a Vermeulen, Jessica $u Johnson & Johnson, Leiden, The Netherlands
700    1_
$a Krevvata, Maria $u Johnson & Johnson, Spring House, PA, USA
700    1_
$a Lopez-Masi, Lorena $u Johnson & Johnson, Raritan, NJ, USA
700    1_
$a Carey, Jodi $u Johnson & Johnson, Spring House, PA, USA
700    1_
$a Rowe, Melissa $u Johnson & Johnson, High Wycombe, UK
700    1_
$a Carson, Robin $u Johnson & Johnson, Spring House, PA, USA
700    1_
$a Zweegman, Sonja $u Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
773    0_
$w MED00003459 $t Nature medicine $x 1546-170X $g Roč. 31, č. 4 (2025), s. 1195-1202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39910273 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092754 $b ABA008
999    __
$a ok $b bmc $g 2366850 $s 1253406
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 31 $c 4 $d 1195-1202 $e 20250205 $i 1546-170X $m Nature medicine $n Nat Med $x MED00003459
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options